Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 238Lymphoma 235Lymphoma, Non-Hodgkin 203Leukemia, Lymphocytic, Chronic, B-Cell 186Lymphoma, Large B-Cell, Diffuse 178Lymphoma, Follicular 173Lymphoma, B-Cell 112Lymphoma, Mantle-Cell 107Hodgkin Disease 105Leukemia, Myeloid, Acute 102Recurrence 97Multiple Myeloma 91Burkitt Lymphoma 90Leukemia 76Neoplasms 68Lymphoma, B-Cell, Marginal Zone 60Hematologic Neoplasms 59Myelodysplastic Syndromes 56Waldenstrom Macroglobulinemia 48Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 43Lymphoma, T-Cell 42Lymphoma, T-Cell, Peripheral 36Lymphoma, T-Cell, Cutaneous 31Leukemia, Biphenotypic, Acute 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Leukemia, B-Cell 26Mycosis Fungoides 25Lymphoma, Large-Cell, Anaplastic 25Sarcoma 23Breast Neoplasms 22

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × Lymphoid × 90 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡